1. Home
  2. GNPX vs EKSO Comparison

GNPX vs EKSO Comparison

Compare GNPX & EKSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • EKSO
  • Stock Information
  • Founded
  • GNPX 2009
  • EKSO 2005
  • Country
  • GNPX United States
  • EKSO United States
  • Employees
  • GNPX N/A
  • EKSO N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • EKSO Medical/Dental Instruments
  • Sector
  • GNPX Health Care
  • EKSO Health Care
  • Exchange
  • GNPX Nasdaq
  • EKSO Nasdaq
  • Market Cap
  • GNPX 9.1M
  • EKSO 7.7M
  • IPO Year
  • GNPX 2018
  • EKSO N/A
  • Fundamental
  • Price
  • GNPX $0.23
  • EKSO $3.49
  • Analyst Decision
  • GNPX
  • EKSO Strong Buy
  • Analyst Count
  • GNPX 0
  • EKSO 2
  • Target Price
  • GNPX N/A
  • EKSO $34.75
  • AVG Volume (30 Days)
  • GNPX 1.1M
  • EKSO 142.8K
  • Earning Date
  • GNPX 08-12-2025
  • EKSO 07-28-2025
  • Dividend Yield
  • GNPX N/A
  • EKSO N/A
  • EPS Growth
  • GNPX N/A
  • EKSO N/A
  • EPS
  • GNPX N/A
  • EKSO N/A
  • Revenue
  • GNPX N/A
  • EKSO $14,651,000.00
  • Revenue This Year
  • GNPX N/A
  • EKSO $0.20
  • Revenue Next Year
  • GNPX N/A
  • EKSO $42.29
  • P/E Ratio
  • GNPX N/A
  • EKSO N/A
  • Revenue Growth
  • GNPX N/A
  • EKSO N/A
  • 52 Week Low
  • GNPX $0.20
  • EKSO $2.73
  • 52 Week High
  • GNPX $3.97
  • EKSO $19.20
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 39.16
  • EKSO 44.83
  • Support Level
  • GNPX $0.25
  • EKSO $3.30
  • Resistance Level
  • GNPX $0.29
  • EKSO $5.60
  • Average True Range (ATR)
  • GNPX 0.02
  • EKSO 0.46
  • MACD
  • GNPX -0.01
  • EKSO -0.02
  • Stochastic Oscillator
  • GNPX 12.22
  • EKSO 13.38

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

Share on Social Networks: